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Summary: Prostate-specific antigen is found in the prostate in two forms, one with a low (30 000) and one
with a high (100000) relative molecular mass. The latter has recently been found to be a complex of prostate-
specific antigen with aj-antichymotrypsin.
Immunoluminometric assays were designed for the prostate-specific antigen-ocj-antichymotrypsin complex äs
well äs for (Xi-antichymotrypsin, the former being compared with a commercially available radioimmunoassay
for prostate-specific antigen (ProsChek RIA — Yang Laboratories).
The precision of the immunoluminometric assays was acceptable (intra-assay Variation < 7%; inter-assay
Variation < 8.5%) in the measuring ranges 0—90 g/l for the prostate-specific antigen-arantichymotrypsin
complex and 0—12 g/l for arantichymotrypsin.
The correlation between the assays for prostate-specific antigen and prostate-specific antigen-aj-antichymo-
trypsin complex was acceptable, showing a correlation coefficient r = 0.83 after double logarithmic transfor-
mation, or r = 0.85 using the Spearman rank correlation on 131 data pairs.
Extremely high arantichymotrypsin levels (above 2 g/l) caused interference in the prostate-specific antigen-
arantichymötrypsin complex assay. Such levels, although rare, are encountered in pulmonary inflammatory
disease.
The reference ranges for the three assays were found to be äs follows:
prostate-specific antigen 0.13—4.63 g/l,
prostate-specific antigeii-ai-antichymotrypsin complex 0.08 — 1.78 g/l, and for
ai-antichymotrypsin 0.27—0.61 g/l.
These values were obtained from 82 höspitalised males fpr the first two assays and from 80 males and females
free from infection fpf the latter. %
Purified prostate-specific antigen (Mr 30000) does not react in the prostate-specific antigen-arantichymo-
trypsin complex as$ay; a concentration of 200 /1 generates a signal whieh is less than that from the first
Standard (0.04 g/l).
In three cases of metästatic cancer of the prostate, discrepancies were found in the values from the prostate-
specific antigen assay (8.56, 30.0 and 107 g/l) and the prostate-specific antigen-arantichymotrypsin complex
assay (0.78, 3.72 and 1,24 jig/1). This may indieate the production of an altered prostate-specific antigen,
which was unable to complex with arantichymotrypsin.
The new assay is not suitable äs a screening assay for prostatic cancer, but it may be of interest for detecting
metästatic disease.
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Introduction
The determination of serum prostate-specific antigen
(l, 2) has been shown to be a better diagnostic indi-
cator than tartrate-inhibited or prostate-specific acid
phosphatase (3,4). Although prostate-specific antigen
has a better diagnostic sensitivity and specificity than
its predecessors, it is unsuitable for screening for pros-
tatic cancer (7), because many patients with benign
disease of the prostate show elevated values in assays
using this antigen (5, 6).
Since prostate-specific antigen is coniplexed with Oi-
antichymotrypsin (8), most probably to neutralise the
protease activity of prostate-specific antigen (9) (anal-
ogous to the formation of elastase-oCi-antitrypsin com-
plexes in serum (10)), an assay was established to
measure prostate-specific antigen-aj-antichymotryp-
sin complexes in serum.
The assay was compared with a classical radioim-
munoassay for prostate-specific antigen (11), s well
s with an irnmunoluminometric assay for serum oCi-
antichymotrypsin. The latter assay was used to test
for the possible influence of high native oti-antichy-




Antibodies to prostate-specific antigen were obtained from
DAKO (Hamburg, Germany).
Antibodies to arantichymotrypsin were purchased from
DAKO and Atlantic Antibodies (Baxter, Munich, Germany).
Polystyrene balls for the solid ph se (6.4 mm diameter) were
ordered from Spherotech Kugeln (Fulda, Germany).
Streptavidin was purchased from Calbiochem-Behring (Frank-
furt a. M., Germany), and amidocaproylbiotin-N-hydroxysuc-
cinimide ester from Sigma (Deisenhofen, Germany).
The luminescent label, 9-(4-succinimidobutyl-N-ethyl) amino-
benzo (0 phthalazine-1,4 (2H, 3H) dione (ABEN-H), was syn-
thesised according to Schroeder et al. (12) and was coupled to
antibodies after synthesis of its N-hydroxysuccinimide ester
(13).
The radioimmunoassay kit used for comparison was the pros-
tate-specific antigen (ProsChek RIA) from Yang Laboratories
(1BL, Hamburg, Germany). Standards for the prostate-specific
antigen-oci-antichymotrypsin complex assay were calibrated in
terms of the prostate-specific antigen content in both the Yang
RIA and Hybritech prostate-specific antigen-immunoradiome-
tric assay.
The ai-antichymotrypsin Standard serum was obtained from
Behringwerke (Marburg a. d. L., Germany), (Code No. OUCL
06/07).
Radioactivity was counted in an automatic gamma spectro-
meter (LKB 1277 Gammamaster) with on-line PC (Pharmacia,
Freiburg, Germany). Liiminescence was measured in a 250-
sample semiautomatic luminometer LB 952-16T — (EG & G
Berthold, Wildbad, Germany).
The assay schemes for prostate-specific antigen, arantichy-
motrypsin and prostate-specific antigen-ai-antichymotrypsin
complex are shown in tables la—Ic.
For establishinent of reference ranges and to check for speci-
ficity ("paraneoplastic-prostate-specific antigen" production in
other tumours), samples were obtained from healthy volunteers
and patients attending the urology clinic, s well s patients
with renal insufficiency, lung cancer and other benign, non-
prostatic diseases. Data from 270 patients were studied during
the evalu tion period.
Statistics
Statistics were carried out using non-parametric tests. The
Mann-Whitney U-Test was used for independent variables, the
Wilcoxon signed rank test for paired data and the Spearman
rank test for regression analysis. The data distribution was
checked with the Kolmogorov Smirnofftest at the level α = 0.05.
Tab. 1. Assay schemes for prostate-specific antigen, oti-antichy-
motrypsin and prostate-specific antigen-aj-antichymo-
trypsin complexes
a) Prostate-specific antigen radioimmunoassay — Yang labo-
ratories (ProsChek PSA-RIA)
200 μΐ Standard/sample
200 μΐ 125I-labelled prostate-specific antigen
200 μΐ Anti-prostate-specific antigen
Incubate overnight at ambient temperature
500 μΐ Precipitating antibody/p lyethylene glycol
Incubate 15 min at 2000 g
Decant supernatant
Count precipitate for l min
b) (x.j-antichymotrypsin immunoluminometric assay
10 μΐ Standard or sample (l : 1000 dilution)
200 μΐ assay buffer
l Anti aj-antichymotrypsin-coated ball (DAKO)
Incubate 60 min at ambient temperature and 170 min"1
Wash with 2 χ 5 ml aqua bidest
200 μΐ ABEN-labelled anti arantichymotrypsin
Incubate and wash s above, transfer ball to fresh cuvette,
pipette 300 μΐ catalase, load luminometer, inject 300 μί
NaOH/H202
Integrate light signal for 2 s




l Anti prostate-specific antigen-coated ball (DAKO) · ·
Incubate for 90 min at ambient temperature and 170 min"1
Wash with 4 χ 5 ml aqua bidest
200 μΐ biotin-labelled anti arantichymotrypsin
Incubate and wash s above
200 μΐ streptavidin-ABEN
Incubate 30 min, wash s above, and prpceed s in b) above
Integrate light signal over 2 s
Ranges covered by the Standard curvesfor each assay
Prostate-specific antigen 0-^-50 μg/l
aj-Antichymotrypsin 0—12.4 g/l
.Prostate-specific antigen-arantichymo- 0—90 μg/l
trypsin complex
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Experiments and Results
Establishment of reference ranges
The prostate-specific antigen radioimmunoassay was
carried out according to the manufacturer's instruc-
tions using the overnight incubation at room temper-
ature.
Tab. 2. Quality control data for all 3 assays
a) Prostate-specific antigen radioimmunoassay (Yang Labora-
tories)
Precision profile data








































































*) Inter-assay precision was determined in each case in 20
consectutive assays from the means of duplicate determi-
nations.
The reference ranges (95% confidence limits) estab-
lished in 82 hospitalised male patients with non-pros-
tate diseases and without bacterial infections were
0.13-4.63 μg/l (median 1.60) for prostate-specific
antigen, and 0.08-1.78 μg/l (median 0.60) for pros-
tate-specific antigen-ai-antichymotrypsin complex.
The reference ranges (95% confidence limits) were
established for arantichymotrypsin in 80 patients,
male and female, attending outpatient clinics, who
were free from bacterial or viral infection and malig-
nant disease. The 95% confidence limits for aranti-
chymotrypsin were 0.27-0.61 g/l (median 0.38).
There was no difference between arantichymotrypsin
in males and females (p > 0.75).
There was a positive correlation between serum pros-
tate-specific antigen and prostate-specific antigen-ocr
antichymotrypsin complex in the reference group
(r = 0.63, p < 0.01, slope 0.25, intercept 0.27) and
no difference between serum and plasma values. There
was a close correlation between prostate-specific an-
tigen and prostate-specific antigen-arantichymotryp-
sin complex over the whole concentration r nge
(0—410 μg/l arantichymotrypsin; 0—270 μg/l pros-
tate-specific antigen-ocrantichymotrypsin complex)
(r = 0.85, p < 0.01, slope 0.57, intercept -0.92).
The correlation between arantichymotrypsin in
serum and plasma was excellent (r = 1.00, slope
= 0.998, intercept = 0.03 g/l), so that plasma or
serum samples could be used for all three assays. In
contrast to other studies (14), prostate-specific antigen
was present at detectable levels in serum from females.
This is not surprising, since prostate-specific antigen
has been detected histochemically in urethral glands
from both sexes (15).
Assay precision data
Table 2 shows the basic quality control data for all 3
assays. The intra-assay precision was represented by
a compound precision profile, the inter-assay preci-
sion by conventional means, i. e. from the measure-
ment of control sera in consecutive assays.
Specificity of the prostate-specific antigen-
(Xi-antichymotrypsin complex assay
Levels of up to 200 μg/l purified prostate-specific
antigen measured in the prostate-specific antigen-ai-
antichymotrypsin complex assay gave values less than
the first Standard (0.15 μg/l)9 showing the assay to be
specific for prostate-specific antigen-at-antichymo-
trypsin complexes.
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Neither prostate-specific antigen-ot! antitrypsin nor
prostate-specific antigen-a2 macroglobulin complexes
were detectable in serum or plasma when measured
with sandwich assays, showing that prostate-specific
antigen forms specific complexes with oti-antichymo-
trypsin (8) but most probably not with other antipro-
teases. Attempts at complexing oti-antichymotrypsin,
in the form of fresh plasma, with purified prostate-
specific antigen (Mr 30000) did not result in com-
plexes being formed in vitro.
This is in contrast to purified neutrophil elastase,
which readily forms complexes with tti-antiproteinase
and a2-macroglobulin present in fresh plasma.
Experimental groups
Sex-related differences in concentrations of prostate-
specific antigen and prostate-specific antigen-aranti-
chymotrypsin complex in healthy subjects
The levels of prostate-specific antigen were, s to be
expected, higher in healthy men than in healthy
women (men-median 1.27 μg/l, women-median 0.16
μg/l, p < 0.01 Mann Whitney U-test). The levels of
prostate-specific antigen-ai-antichymotrypsin com-
plex were also higher in healthy men than in healthy
women (men-median 1.18 μ§/1, women-median 0.78
μg/l), although this difference was not significant.
Patients with prostatic cancer and benign hyperplasia
or hypertrophy of the prostate
Assays employing prostate-specific antigen and pros-
tate-specific antigen-ot! -antichymotrypsin complex
were compared for their ability to differentiate be-
tween benign and malignant prostate disease.
Twenty patients with clinically confirmed prostate
carcinomata with (12/20) and without (8/20) metas-
tasis were compared with 15 patients presenting with
benign prostatic hypertrophy or hyperplasia (9/15) or
prostatitis (6/15).
Whereas all carcinoma/adenoma patients h d path-
ologically elevated concentrations of prostate-specific
antigen, normal prostate-specific antigen-ocrantichy-
motrypsin complex levels were seen in three cases of
prostate carcinoma. In the benign prostatic hyperpla-
sia group 6/9 presented with elevated prostate-specific
antigen and 5/9 with elevated prostate-specific anti-
gen-ai-antichymotrypsin complex. In the patients
with prostatitis 4/6 presented with elevated prostate-
specific antigen and 3/6 with elevated prostate-specific
antigen-a^antichymotrypsin complex. The results are
summarised in table 3a—3c.
Tab. 3. Values obtained from patients with prostatic disease





a) Prostatic adeno carcinomata with metas tasis
1 pre-op 46.4























































c) Benign prostate hyperplasia and prostatitis (P)
21 P
22 P before therapy
control
23 ̂















































Patients with other urological disorders
30 male patients attending the urology cliriic for neph-
rolithiasis (n = 20) and urinary tr ct infections
(n = 10) were taken s a control group. The r nge of
prostate-specifie antigen concentrations was 0.27—
4.21 μg/l (median 1.73 μg/l) and for prostate-specific
antigen-arantichymotrypsin complex 0.16-2.87 μ̂ /1
(median 0.66 μg/l). The values correlated with each
other in a simil r way t those frorh healthy iridivid-
c-uals (r = 0.53, p < 0.005). Twp patients had elevated
results, one in each assay. . l
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Fig. 1. Ten selected cases showing the efiects of increasing arantichymotrypsin concentrations in serum on the results obtained
in the prostate-specific antigen-arantichymotrypsin complex assay. The concentrations of prostate-specific antigen in
these samples is also given.
Bacterial and viral infections — Effects on measured
concentrations of prostate-specific anligen-v.rantichy-
motrypsin complex
There was a correlation between arantichymotrypsin
levels and measured prostate-specific antigen-aran-
tichymotrypsin complex levels in patients with bac-
terial and or viral infection, but without prostate
disease, showing that high arantichymotrypsin levels
may lead to an increase in measured prostate-specific
antigen-arantichyrnotrypsin complex concentrations
in such patients. Figure l shows the relationship be-
tween prostate-specific antigen, prostate-specific an-
tigen-arantichymotrypsin complex and elevated ar
antichymotrypsin based on 10 selected patients.
100
0.1




Fig. 2. Correlation between prostate-specific antigen and pros-.
tate-specific antigen-arantichymotrypsin complex in
131 subjects with normal arantiehymotrypsin serum
concentrations.
The correlation coefficient was 0.829 and p < 0,001.
The regression line equation was (logy) = 0.74 (log x)
- 0.21.
The correlation between prostate-specific antigen and
prostate-specific antigen-ai-antichymotrypsin com-
plex is markedly better (r = 0.85 compared with
r = 0.57) when patients with high arantichymotryp-
sin are excluded (fig. 2).
Values of arantichymotrypsin above 2 g/l (more than
3 times the upper limit of the reference r nge described
above) are likely to give rise to pathological values
for prostate-specific antigen-α! -antichymotrypsin
complex. This means that in patients with bacterial
infections, care must be taken in interpreting prostate-
specific antigen-ai-antichymotrypsin complex levels.
In patients with elevated prostate-specific antigen lev-
els and normal or slightly elevated arantichymotryp-
sin the correlation between prostate-specific antigen
and prostate-specific antigen-α! -antichymotrypsin
complex is excellent. The slope of the regression line
is not unity, due to the materials used for calibration.
Purified prostate-specific antigen (Mr 30 000) is used
for calibrating the commercial kits, whereas naturally-
occurring prostate-specific antigen-arantichymotryp-
sin complexes (Mr 100000) were prevalent in the
serum used for calibrating the sandwich assay for
prostate-specific antigen-arantichymotrypsin com-
plex.
Extra wash Steps reduce carry-over considerably with-
out significantly reducing the specific binding. In a
study on 63 urological patients, without prostatic
cancer and with normal and elevated arantichymo-
trypsin levels, all were assayed for prostate-specific
antigen, s well s for prostate-specific antigen-ar
antichymotrypsin complex with 2 χ 5 ml wash Steps
(assay method 1) and 4 χ 5 ml wash Steps (assay
method 2).
The results are shown in table 4. Prostate-specific
antigen-arantichymotrypsin complex levels were sig-
nificantly lower in assay method 2. Patients with
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 29,1991 / No. 12
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Tab. 4. Eflect of washing on the unspecific adsorption of ocr
antichymotrypsin in the prostate-specific antigen-ar
antichymotrypsin complex assay on 63 samples with
prostate-specific antigen levels less than 6 μg/l.
Range of prostate-specific antigen 0.19-5.84 μg/l (median 1.73
Range of arantichymotrypsin 0.22-2.01 g/l (median 0.52 g/l).
Assay method l — with 2 χ 5 ml wash Steps between incuba-
tions.
Range of prostate-specific antigen-ai-antichymotrypsin com-
plex 0.14-2.87 g/l (median 0.68 g/l).
Assay method 2 — with 4 χ 5 ml wash Steps between incuba-
tions.
Range of prostate-specific antigen-ocraniichymotrypsin com-
plex 0.08-1.64 g/l (median 0.44 μg/l).
Wilcoxon signed rank test assay method l vs assay method 2
p < 0.001.
Linear regression data prostate-specific antigen vs prostate^
specific antigen-ai-antichymotrypsin complex
Assay method l - r (Spearman) 0.507 p < 0.005
Assay method 2 - r (Spearman) 0.483 p < 0.005
elevated αι-antichymotrypsin showed much reduced
non-specific binding after increased washing (see fig-
ure 3 — selected sera).
Prostate-specific antigen, prostate-specific antigen-a.r
antichymotrypsin complex levels in other groups with
non-prostatic disease
Four from 6 females with pulmonary infections had
falsely elevated prostate-specific antigen-ai-antichy-
motrypsin complex due to interference from exces-
sively high αι-antichymotrypsin concentrations in
their serum. These four patients are number 7, 8, 9
and 10 in figurel.
Reports have been published of antibodies to pros-
tate-specific antigen, which may give rise to measur-
able prostate-specific antigen concentrations in
women (11). In the present investigation, prostate-
specific antigen levels were therefore also studied in
sera from women, s part of a general study of "prob-
lem patients" (with regard to latioratory tests). A 46-
year old woman was found to have "prostate-specific
antigen-antibodies" which gave rise to elevated "pros-
tate-specific antigen" levels in the prostate-specific
antigen radioimmunoassay. In this case, a prostate-
specific antigen value of 5.2 μg/l (prostate-specific
antigen-ai-antichymotrypsin complex 0.20 μg/l) was
measured. The serum had a high unspecific binding
of labelled prostate-specific antigen after polyethylene
glycol precipitation, which indicated the presence of
antibodies to prostate-specific antigen. A similar case
was seen in a 54 year old man with nephritis who had
"prostate-specific antigen-levels" of 21.8 μg/l, pros-
tate-specific antigen-ai-antichymotrypsin complex
levels of 0.27 and αι-antichymotrypsin of 0.58 g/l.
Sera from a group of reiial insufficiency patients, s
well s those with proven Jung carcinom , were also
checked for "prostate-specific antigen" and "prostate-
specific antigen-ai-antichymotrypsin complex".
In one case of renal insufficiency, a prostate-specific
antigen level of 5.3 μg/l was measured. Prostate-spe-
cific antigen-ai-antichymotrypsin complex was nor-
mal (1.20 μg/l). A 90 year old man with a phimosis
had elevated prostate-specific antigen (pre-op. 10.1
μg/l, post-op. 11.4 μg/l) s well s prostate-specific
antigen-arantichymotrypsin cojnplex (pre-op. 2.86
μg/l, post-op. 2.14 μg/l). in one case of prostatic
cancer treated by bilateral orchidectomy, prostate-
specific antigen levels were 0.27 μg/l and prostate-
specific antigen-ai-antichymotrypsin complex 0.09
5 6
Patient No.
Fig. 3. Selected patients with normal serum prostate-specific antigen levels and with grossly elevated arantichymotrypsin (> 2 g/l)
in serum. The effects on "prostate-specific antigen-oci-antschymotrypsin complex levels" by washing with 2 χ 5 ml and
4 χ 5 ml between incubation Steps are shown.
» i
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μg/l six months after Operation. Nephrolithiasis pa-
tients (n = 20) and patients with urinary tract infec-
tions (n = 10) had normal levels of prostate-specific
antigen, prostate-specific antigen-arantichymotryp-
sin complex and arantichymotrypsin. One woman
with lung cancer had elevated levels of prostate-spe-
cific antigen and prostate-specific antigen-arantichy-
motrypsin.
Discussion
Although the introduction of the assay for prostate-
specific antigen has led to a better discrimination
between patients with prostatic cancer and those with
inflammation of the prostate, there is still some over-
lap between both groups, which reduces the clinical
specificity and sensitivity of the test. As it has been
shown that prostate-specific antigen normally circu-
lates s a complex with ai-antichymotrypsin (8), an
assay was developed to see whether the measurement
of prostate-specific antigen-arantichymotrypsin com-
plex would improve the diagnostic value of the pros-
tate-specific antigen determination. This would be
analogous to the measurement of elastase-oci-antitryp-
sin (10).
The results show that the assay for prostate-specific
antigen-arantichymotrypsin complex is much quicker
than that for prostate-specific antigen, s well s need-
ing a smaller sample volume. Difficulties arise, how-
ever, due to non-specific adsorption of arantichy-
motrypsin to the solid phase and to the production
of prostate-specific antigen not coupled to arantichy-
motrypsin, s seen in three patients with metastasis.
Increasing the number of wash steps (4 χ 5 ml) be-
tween each incubation reduces the unspeciflc adsorp-
tion effects due to arantichymotrypsin, although it
does not completely alleviate the problem. Although
falsely elevated results do not become apparent until
αι-antichymotrypsin levels exceed three times the up-
per limit of the reference r nge for healthy volunteers,
such levels can occur in extreme cases of bacterial
infection, s seen in cases of pulmonary sepsis (see
fig. 1), where the female patients with "elevated pros-
tate-specific antigen^arantichyinotrypsin complex"
were all from the pulmonary unit.
The advantages of the prostate-specific antigen-ar
antichymotrypsin complex assay are its short incu-
bation times and its ability to give "correct answers"
in the rare cases of patients with "anti-prostate-spe-
cific antigen-like activity" (11).
As both Afr 30000 and MT100000 "prostate-specific
antigen" (free and complexed) have been seen in elec-
trophoresis of seminal fluid (8), the ratio of prostate-
specific antigen to prostate-specific antigen-aranti-
chymotrypsin complex may be a useful clinical indi-
cator, but this involves the performance of an addi-
tional laboratory test.
Purified prostate-specific antigen (Mr 30000) (1) did
not complex with a3-antichymotrypsin in plasma,
showing either that the active formation of complexes
normally takes place in the prostate, or that the pros-
tate-specific antigen had lost its ability to combine
with αι-antichymotrypsin during purification.
There were interesting cases where a woman with
"prostate-specific antigen-like immunoreactivity" had
an elevated unspecific binding of prostate-specific an-
tigen tracer if the serum was precipitated with poly-
ethylene glycol (end concentration 150 g/l), which
pointed to the presence of antibodies to prostate-
specific antigen. One man with nephritis also had
antibodies to prostate-specific antigen. Three cases of
metastasing prostate carcinoma had discrepant values
for prostate-specific antigen and prostate-specific an-
tigen-arantichymotrypsin complex (prostate-specific
antigen 8.56, 30.0 and 107 μg/l, prostate-specific an-
tigen-arantichymotrypsin complex 0.78, 3.72 and
1.24 μg/l) (Cases 10-12 - tab. 3a). The latter cases
point to the production of an abnormal neoplastic
prostate-specific antigen which was incapable of bind-
ing to arantichymotrypsin in the normal way, s ar
antichymotrypsin was present in serum in normal
concentrations.
To conclude, both assays can be used in the diagnosis
and follow up of prostatic cancer, the results from the
prostate-specific antigen-arantichymotrypsin com-
plex assay being available on the same day, using a
sample of only 110 μΐ for a duplicate determination.
This is offset by the fact that grossly elevated levels
of aj-antichymotrypsin may give rise to falsely ele-
vated prostate-specific antigen-ai-antichymotrypsin
complex levels in serum or plasma, which can be
reduced but not fully excluded by increasing the num-
ber of wash Steps.
Further experimentation is needed to examine
whether the prostate-specific antigen-arantichymo-
trypsin complex assay can be used in post-op. follow-
up and early diagnosis of metastases. Whether the
ratio, free: complexed prostate-specific antigen, may
act s an indicator of metastatic growth (supported
by cases 10—12, tab. 3a) must also be investigated
further.
In the light of the present results, prostate-specific
antigen-arantichymotrypsin complex alone is not ex-
pected to be more specific than prostate-specific an-
tigen or prostate acid-phosphatase s a screening pa-
rameter.
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